Show simple item record

dc.contributor.authorBuehler, P.W.
dc.contributor.authorHumar, R.
dc.contributor.authorSchaer, D.J.
dc.date.accessioned2020-04-01T20:14:40Z
dc.date.available2020-04-01T20:14:40Z
dc.date.issued2020
dc.identifier.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85082015509&doi=10.1016%2fj.molmed.2020.02.004&partnerID=40&md5=7a61cc33ace36afc4b1675da5da39a86
dc.identifier.urihttp://hdl.handle.net/10713/12471
dc.description.abstractHemolysis and accumulation of cell-free hemoglobin (Hb) in the circulation or in confined tissue compartments such as the subarachnoid space is an important driver of disease. Haptoglobin is the Hb binding and clearance protein in human plasma and an efficient antagonist of Hb toxicity resulting from physiological red blood cell turnover. However, endogenous concentrations of haptoglobin are insufficient to provide protection against Hb-driven disease processes in conditions such as sickle cell anemia, sepsis, transfusion reactions, medical-device associated hemolysis, or after a subarachnoid hemorrhage. As a result, there is increasing interest in developing haptoglobin therapeutics to target 'toxic' cell-free Hb exposures. Here, we discuss key concepts of Hb toxicity and provide a perspective on the use of haptoglobin as a therapeutic protein. Copyright 2020 The Authorsen_US
dc.description.urihttps://doi.org/10.1016/j.molmed.2020.02.004en_US
dc.language.isoen_USen_US
dc.publisherElsevier Ltden_US
dc.relation.ispartofTrends in Molecular Medicine
dc.subjecthaptoglobinen_US
dc.subjecthemeen_US
dc.subjecthemoglobinen_US
dc.subjecthemolysisen_US
dc.subjectsepsisen_US
dc.subjectsickle cell diseaseen_US
dc.subjectsubarachnoid hemorrhageen_US
dc.subjecttransfusionen_US
dc.titleHaptoglobin Therapeutics and Compartmentalization of Cell-Free Hemoglobin Toxicityen_US
dc.typeArticleen_US
dc.identifier.doi10.1016/j.molmed.2020.02.004


Files in this item

Thumbnail
Name:
Publisher version

This item appears in the following Collection(s)

Show simple item record